Haemonetics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Haemonetics stock has a consensus rating of "Buy" and an average price target of $108.4. The average 1-year stock price forecast is 5.32% higher than the current stock price, while the lowest is $86 (-16.44%) and the highest is $125 (+21.45%).

Price Target: $108.4 (+5.32%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$86	$108.4	$112.5	$125
Change	-16.44%	+5.32%	+9.31%	+21.45%

Analyst Ratings

The average analyst rating for Haemonetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	3	3	4	4	4	4
Buy	4	4	4	4	4	4
Hold	4	4	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	11	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andrew Cooper Raymond James	Raymond James	Buy Maintains $105 → $125	Buy	Maintains	$105 → $125	+21.45%	Sep 3, 2026
David Rescott Robert W. Baird	Robert W. Baird	Buy Maintains $96 → $119	Buy	Maintains	$96 → $119	+15.62%	Aug 21, 2026
Michael Petusky Barrington	Barrington	Buy Maintains $95 → $118	Buy	Maintains	$95 → $118	+14.65%	Aug 19, 2026
Michael Matson Needham	Needham	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Aug 18, 2026
Travis Steed Bank of America Securities	Bank of America Securities	Buy Reiterates $1 → $120	Buy	Reiterates	$1 → $120	+16.60%	Aug 18, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.41B

from 1.33B

6.05%

from 1.33B

Revenue Next Year

1.49B

from 1.41B

5.25%

from 1.41B

EPS This Year

5.30

from 4.96

6.80%

from 4.96

EPS Next Year

5.74

from 5.30

8.35%

from 5.30

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Apr 2, 2022	Apr 1, 2023	Mar 30, 2024	Mar 29, 2025	Mar 28, 2026	Mar 31, 2027
Revenue	993.20M	1.17B	1.31B	1.36B	1.33B	1.41B
Revenue Growth	14.10%	17.67%	12.01%	3.96%	-1.97%	6.05%
Gross Profit	530.77M	622.87M	708.57M	778.55M	792.87M	861.97M
Gross Margin	53.44%	53.30%	54.13%	57.21%	59.43%	60.93%
Operating Income	105.17M	167.20M	205.49M	247.10M	251.53M	367.28M
Net Income	43.38M	115.40M	117.56M	167.68M	97.31M	177.42M
EPS	-	-	-	-	4.96	5.30
EPS Growth	-	-	-	-	8.53%	6.80%
Forward PE	23.82	25.45	20.49	13.21	10.46	19.43
Free Cash Flow	88.90M	50.09M	148.53M	183.89M	298.09M	317.00M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2027	2028	2029
High	1.4B
Avg	1.4B
Low	1.4B

Revenue Growth

Chart

Revenue Growth	2027	2028	2029
High	6.9%
Avg	6.1%
Low	4.6%

EPS Forecast

Chart

EPS	2027	2028	2029
High	5.36
Avg	5.30
Low	5.25

EPS Growth

Chart

EPS Growth	2027	2028	2029
High	8.1%
Avg	6.8%
Low	5.8%